2022
DOI: 10.1016/j.clnesp.2022.02.122
|View full text |Cite
|
Sign up to set email alerts
|

FTO genotype was associated with breast cancer in HER2 negative patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 21 publications
0
2
0
1
Order By: Relevance
“…Az rs9939609 génvariáns és az emlőrák ER-, PR-és TP53statusa között nem igazolódott összefüggés. Felmerült tehát, hogy az FTO rs9939609 SNP potenciális terápiás célpont lehet HER2-negatív emlőrákos betegek kezelésében [53].…”
Section: Az Elhízás a Diabetes éS A Daganatok Kapcsolata Génasszociác...unclassified
“…Az rs9939609 génvariáns és az emlőrák ER-, PR-és TP53statusa között nem igazolódott összefüggés. Felmerült tehát, hogy az FTO rs9939609 SNP potenciális terápiás célpont lehet HER2-negatív emlőrákos betegek kezelésében [53].…”
Section: Az Elhízás a Diabetes éS A Daganatok Kapcsolata Génasszociác...unclassified
“…Data from breast cancer patients and controls showed that SNP rs1477196 and rs9939609, independently and together, as well as rs1477196 contribute to breast cancer risk [28]. Rs9939609 is correlated with patients who are HER-2-negative [39]. Evidence is mixed about whether rs9939609 is important in the development of breast cancer in those who are overweight and whether rs1477196 correlates with a diagnosis of stage 1 breast cancer [28] [35] [40] [41].…”
Section: Single Nucleotide Polymorphisms Mutations and Breast Cancermentioning
confidence: 99%
“…FTO is responsible for controlling fatty acid transport, adipogenesis, fat metabolism, and obesity susceptibility. Single nucleotide polymorphisms (SNPs) of the FTO gene might be associated with various functions in different BC subtypes ( Montazeri et al, 2022 ). It has been demonstrated that FTO expression is deregulated in a variety of tumors, including acute myeloid leukemia (AML), gastric cancer (GC), cervical squamous cell carcinoma (CSCC), ovarian cancer (OC), and BC ( Deng et al, 2018 ).…”
Section: The Role Of N6-methyladenosine Modification In Breast Cancer...mentioning
confidence: 99%